Bendamustine Plus Brentuximab Vedotin in HL and CD30+ PTCL in First Salvage Setting

Summary

This is a single-arm, open-label, multicenter, phase 2 clinical trial aimed at evaluating the efficacy and safety of the combination of bendamustine and brentuximab vedotin as a first salvage therapy in patients with relapsed or refractory Hodgkin's lymphoma or PTCL. A total of 25 patients with PTCL, and 40 with Hodgkin's lymphoma are expected to be treated according to this treatment protocol.

Timeline

Start

2015-12-23

Primary completion

2019-09-13

Completion

2020-06-30

Drugs

Indications